Generic Stay May Be Shortened Based Only On Behavior In Trial – Appeals Court

The 30-month stay of approval on generic products may be shortened if the brand firm delays responding to a patent infringement action, but not for delays in the resolution of the overall patent dispute, the Court of Appeals for the Federal Circuit found